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SUMMARY A new series of 4-carbamoyl-6-(3-thienyl-4,5-dihydropyridazin-
3-(2H)ones 4a-g have been synthesized and tested for their anti-inflammatory and 
analgesic properties. Among the tested compounds, only 41 at 1 mmolelKg showed 
antiinf/ammatory activity that was comparable with that of indomethacin (5 mg I Kg) 
though of shorter duration. Compounds 4a, 4e and especially 4g at 0.2 mmoleslKg 
displayed relevant analgesic activity, 4g being the most potent derivative in the writh-
ing test. Compounds 4c and 4g were found to possess analgesic activity also in the 
hot plate test. 
, 
RIASSUNTO -E stata sintetizzata e valutata l'attivita antinfiammatoria e anal-
gesica di una nuova serie di 4-carbamoil-6-{3-tienil-4,5-diidropiridazin-3(2H)-oni. Fra 
i composti saggiati, solo 41 alia dose di 1 mmolelKg ha mostrato proprieta antin-
fiammatoria comparabite in intensita, ma di minore durata, rispetto a quella del-
l'indometacina assunta come farmaco di rijerimento. D'altra parte alia dose di 0,2 
mmo/il Kg 4a e 4e hanno manijestato una buona attivita analgesica nel writhing test 
mentre it derivato 4g ha dimostrato di essere piu attivo dello stesso farmaco di rije-
rimento. Infine i composti 4c e 4g hanno dimostrato di avere anche attivita analge-
sica nel test della piastra calda. 
(*) An account of this work was communicated at the "3'd International Sympo-
sium on the chemistry and pharmacology of the pyridazines"; Como, 9-11 Sep-
tember 1992. 
(**) To whom correspondence should be addressed . 
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Introduction 
6-Aryl-4,5-dihydropyridazinones 1 represent a well known class of PDE-
III inhibitors with inotropic and vasodilator effects (inodilators) (1,2). Re-
version of 5 and 6 substituents to give 5-aryl-6-methyl-4,5-
dihydropyridazinones 2 caused loss of these properties while it induced in 
some of the tested compounds anti-inflammatory, antithrombotic and an-
tiulcer activities (3). Moreover, the introduction of a variety of carbamoyl 
groups at C-4 of the dihydropyridazinonic ring of 2 gave compounds 3 pro-
vided with significant anti-inflammatory and good analgesic properties. An-
tinociceptive activity was especially displayed by carbamoyl derivatives bea-
ring on the nitrogen a Cl or a CF3 substituted aryl moiety (4). 
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In this context, a new series of 6-IJ-thienyl-3(2H)-oxo-4,5-
dihydropyridazine-4-carboxamides (4a-g), somewhat related with both sets 
of compounds 1 and 3, have been prepared with the aim to study the even-
tual anti-inflammatory and analgesic properties. 
Chemistry 
Synthetit pathway for the title compounds is illustrated in the Scheme. 
The key intermediate 6-thienyl-4-ethoxycarbonyl-4,5-dihydropyridazin-
3(2H)one (5) was prepared in 86070 yield refluxing 2-IJ-thenoylmethylmalonate 
(6) (4) with hydrazine hydrate in 60% aqueous acetic acid. 
Exchange reaction of ester 5 with appropriate amines in refluxing xy-





















Melting points were determined with a Kofler apparatus and are uncorrected. 
IR spectra were registered in nujol mull on a Perkin Elmer Infrared 781 spectrome-
ter. UV spectra were recorded with a Perkin Elmer Lambda 5 spectrometer. IH_ 
NMR spectra were recorded on a Varian XL-200 spectrometer; chemical shits are 
reported as ppm relative to tetramethylsilane as internal standard. Silica gel 60 (Merck; 
230-400 mesh) was used for flash chromatography. TLC on silica gel plates was used 
to control the purity of the products. The elemental analyses (C,H,N, Br,Cl,F,S) 
were within ±Oo4OJo of the theoretical values. 
4-Ethoxycarbonyl-6-{3-thienyl-4,5-dihydropyridazin-3(2H)one (5) 
A mixture of diethyl 2-{:l-thenoilmethylmalonate (6) (5) (5 g; 0.018 mol) and 
hydrazine hydrate (1.80 g; 0.036 mol) in 60% aqueous acetic acid (17.5 m!) was 
refluxed for 1.5 h. After cooling, the solution was poured onto 5% solution of 
NaHC03 (- 80 ml). The white solid which precipitated was collected on filter and 
washed with water to give 3.89 g (86%) of 6, m.p. 156°-158°C. TLC (benzene-acetone, 
7:3): Rf 0.61. 
The analytical sample was crystallized from ethanol or toluene, m.p. 160°-162°C. 
IR cm-I: 3200 (NH); 1720 (ester CO); 1660 (hydrazide CO); 
UV (EtOH) >.max nm (log E): 204.2 (4.96); 286.0 (4.19); 
IH-NMR (CDCb) 0: 1.2 (t, 3H, 1=7.12 Hz); 3.02-3.64 (m, 3H), 4.26 (q, 2H, 
1 = 7.12 Hz); 7.26-7.58 (m, 3H); 8.79 (br s, IH, exchanges with D20). I3C-NMR 50 
MHz (CDCb) 0: 14.00 (q, CH3), 26049 (t, CS-H2); 43.27 (d, C.-H); 62.23 (t, CH2 
of the ester); 125.22 (d, C2'-H and C"-H); 126.76 (d, Cs'-H); 137.96 (s, cn; 147.06 
(s, C6 = N); 163.07 (s, CO); 167.93 (s, CO). 
General procedure for 4-N-substituted-carbamoyl-6-{3-thienyl-4,5 
dihydropyridazin-3-ones (4a-g) 
A solution of the pyridazinonic ester 5 (0.02 mol) and the required amine (0.04 
mol) in anhydrous toluene (300 ml) was refluxed for 20-24 hrs in the presence of 
molecular sieves (4A). The mixture was filtered still hot and evaporated in vacuo 
to give a solid residue which was purified by crystallization (see Table I and 11). 
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TABLE I 
Physical properties of compounds 4a-g 
COMPD YIELD % M.P. cc FORMULA ANALYSES 
4a 90 280-282a Cl5Hl2N302SCl C,H,N,S,Cl 
4b 84 248-250b Cl5Hl2N302SF C,H,N,S,F 
4c 83 273-276c Cl6H 12N30 2SF3 C,H,N,S,F 
4d 79 260-262d Cl6H l5N302S C,H,N,S 
4e 90 30lb Cl6H 15N30 3S C,H,N,S 
4f 88 308b C17H17N303 S C,H,N,S 
4g 86 2l3-216b C15H19N302S C,H,N,S 
• Compound were crystallized from ethyl acetate (a), ethanol (b), methanol (c), acetone (d) . 
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TABLE 11 
UV, /R, IH-NMR spectral data of 4a-g 
UV Amax IR v (cm-I)b IH-NMR (13 ppm)C 
COMPD (logE)a 
3.15-3.27(dd, 2H); 3.67(t, lE); 7.52(ABq, 4H); 7.37-7.42(m, lH, 
203(4.25) 3210,3080 J=2.82Hz, C4,-H); 7.50(d, 1 H, J=5 .06Hz C5,-H) ; 7.7 1(d, lH, 
4a 258(4 .13) 1670,1640 J= 1.66Hz C2,-H); 1O.26(br. s, 1 H, exch with 020); 11.00(br. s, lE, 
sh 282(4.05) 
exch with 020). 
201.8(4.22) 3220,3080 3.23(d, 2H); 3.64(1, lE); 6.98-7.78(m, 7H), 1O.23(br. s, IH, exch 
4b 232.0(4.03) 1670,1640 with 020); 11.04(br. s, lH, exch with 020). 
238.6(4 .05) 
282.4(4.07) 
203 .8(4.40) 3220,3100 3.21-3 .31(m, 2H); 3.70(dd, lE); 735-7.81(m, 7H); 10.39(br. s, IH, 
4c 255.2(4.29) 1690,1650 exch with 020); 1O.88(br. s, IH, exch with 020). 
284 .0(4.19) 
2038(4.54) 3210,3100 2.30(s, JH); 3. 10-3.38(m, 2H): 3.65(dd, lH); 7.07-7.69(m, 7E); 
4d 254 .0(4.36) 1680,1650 9.90(br. s, IH, cxch with 020); 1O.83(br. s, IH, exch. with 020). 
241.0(435) 
281.2(4.34) 
202 .2(4 .29) 3220,3100 3.20(s, JH); 322-3.29(m, 2H); 3.63-3 .81(m, IH); 6.80-7-75(m, 
4e 262.0(4.25) 1680, 1650 7E); 9.90(br. s, IH exch with 020); 1O.87(br. s, lH, exch with 
230.0(4.08) 
°2°)· 359.0(3.57) 
202 .8(4 .33) 3240,3100 1.37(1, JH), 322-3.33(m, 2H); 3.94-4 .04(m, lE); 6.78-7.94(m, 7H); 
4f inf234 0(4 .06) 1680,1650 9.97(br. s, IH. exch with 020); 10.97(br. s, lH, exch with 020). 
inf244.0(4.13) 
2622(4.25) 
203 .4(4 .33) 3340,3250 1.25-1.89(m, IOH); 3.1O-3.40(m. JH); 3.60-3.78(m. lE); 7.34-
4g 2838(4.31) 3100.1680 7.62(m, 4H); 1O.67(br. s, IH, exch with 020) . 
1650 
Spectra were recorded in (a) EtOH for UV, in (b) nujo/ mulls for IR and in (c) CDC/3 with 
a few drops of (CDJhSO for I H-NMR 
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Pharmacology 
Anti-inflammatory activity was evaluated on male albino Wistar rats 
(150 g). For the detection of anti nociceptive properties, male Swiss mice (18-
22 g) were used. In all cases the animals were fed with Morini feed, in pellets, 
and aqua fontis. 
Pharmacological experimental section 
Anti-inflammatory activity: it was evaluated by inhibition of the 
carrageenin-induced hind paw oedema in rats (6). 
One hour before the injection of carrageenin (0.05 ml of 1070 solution) 
the test compounds were administered per os at the dose of 1 mmollKg sus-
pended in 10 mllKg of 10,10 solution of methylcellulose. Activity was evalu-
ated by oedema inhibition at 1,3 and 5 hours after treatment with carragee-
nin and results expressed as mean percent of oedema volume compared to 
that in control animals. 
Peripheral analgesia: it was evaluated through the inhbition of writh-
ings induced by the i.p. injection of formic acid (25 mg/Kg) as 0.25070 solu-
tion in distilled water (7). 
The test compounds were administered per os at the dosage of 115 
mmollKg suspended in 10 mllKg of 10,10 solution of methylcellulose, one 
hour before the formic acid injection. The control animals received only 
the formic acid i.p. and 1070 solution of methylcellulose per os. 
After injection of formic acid writhings were recorded for 20 mins. The 
results are expressed as the percent variation in number of writhings com-
pared to that of the control animals. Indomethacin at the dose of 5 mg/Kg 
was used for comparison. 
Central analgesia: to evaluate this kind of analgesia, typically overspi-
nal, we used the hot-plate test (8). The plate was kept at 55°C and the reac-
tion time (in seconds) was determined on the basis of licking, raising of hind 
paws, jumping and escape reaction. The reaction time was measured be-
fore the administration of the test compounds and 60, 120 and 180 minutes 
after the dosing. The test compounds were administered per os at the dose 
of 115 mmollKg, suspended in a 1070 solution of methylcellulose. Morphine 
at the dose of 10 mg/ Kg s.c. was used for comparison. 
Results and discussion 
Anti-inflammatory activity 
As shown in Table Ill, only 4f at the dose of 1 mmol/ Kg was found 
to have an anti-inflammatory activity comparable with that of indometa-
cin, though of shorter duration. On the contrary compounds 4c and 4d 
produced an increase of the flogistic process. All the other derivatives did 
not display a significant anti-inflammatory property. 
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TABLE III 
Compoud 
Anti-inflammatory activity (rat)" 
070 inhibitionb 
1h 3h 5h 
Indomethacin C -38 -38 -47 
4a + 6 - 3 + 6 
4b -12 -10 -19 
4c - 6 +90 +53 
4d +50 +45 + 37 
4e + 6 -34 -16 
4f - 31 - 31 -16 
4g 0 - 3 + 6 
a) Carrageenin-induced rat paw oedema: "loof inhibition of the oral dose of I mmole/kg suspended in 10 
mllkg of a solution of methyl cellule (1 "10). Groups of six animals were used. 
b) Inibition (-) or increase (+) compared to the oedema volume of control animals. 
c) Indomethacin was administered orally at the dose of 5 mg/ kg 
TABLE IV 
Compoud Analgesic activity: writhings test (mouse) 070 inhibition a 
Indomethacin b -65 







• • • • • • 
a) "10 mhlbllton at the oral dose of 0.2 mmoles/ kg. Groups of eIght ammnals were used. 
b) Indomethacin was administered at the oral dose of 5 mg/ kg 
Analgesic activity 
In the writhing test all the compounds (see Table IV and Fig. 1) showed 
at the dose of 0.2 mmoI!Kg a good peripheral analgesic activity, particu-
lary pronounced for 4a,4e and 4g, the latter being the most potent one respect 
to indomethacin. Therefore, the presence of a cycloalkyl group on the car-
bamoyl function is clearly responsible for the relevant analgesic effect. The 
substitution of cycloalkyl with a p-substituted aryl group, determines a 
decrease of activity that however, still remains good. The effect of the sub-
stituents on the phenyl moiety is not rationaIizable by the data obtained in 
the writhing test. 











Indomethacin 4a 4b 4c 4d 4e 4f 4g 
Fig. 1 
Analgesic activity: Writhings test (mouse) 
TABLE V 
Analgesic activity: hot plate test (mouse) 
Compunda (In parenthesis 1170 change relative to 0 value) 
Mean reaction time (sec ± S.E.) at the 
following times (hours) after treatment 
0 I 2 3 
Control 6.56±0.94 7.14±0.97 ( 9) 7.9 ± 1.07 (20) 7.06 ± 1.42 ( 8) 
Morphine" 7.84 ± 0.23 16.15 ±0.81 (106) 11.78 ± 1.04 (50) 9.94 ± 0.08 (27) 
4a 7.34±0.48 9.33 ±0.83 ( 27) 10.37 ± 1.01 (41) 10.51 ±0.79 (43) 
4b 7.82±0.44 10.44 ± 1.28 (33) 9.26 ± 0.64 (18) 9.33 ±0.75 (19) 
4c 7.15±0.70 7.98 ± 0.97 (12) 11.99 ± 1.61 (68) 9.57 ± 1.13 (34) 
4d 7.75 ± 0.38 7.77 ±0.92 (0) 8.90 ±0.60 (15) 9.45 ± 1.07 (22) 
4e 7.79±0.33 10.74 ± 0.75 (38) 9.70±0.62 (24) 10.31 ±0.59 (32) 
4f 8.20±0.34 11.24 ± 0.32 (37) 10.13 ±0.53 (23) 11.20 ± 0.94 (37) 
4g 6.72 ±0.26 8.62 ±0.54 (28) 9.90 ± 1.15 (47) 10.41 ±0.92 (55) 
• • a) Compounds were gIven orally at the dose of 0.2 mmoles/ kg. Groups of ten ammals were used . 
b) Morphine was administrated at the dose of ID mg/ Kg s.c. 
Results from the hot plate test are indicated in Table V and Fig. 2. Com-
pounds 4c and 4g showed a certain central analgesic activity, 4g being the 
most potent one at the second and third hour after the medication. 
In conclusion, the data currently available seem to indicate that the 
simultaneous substitution of the aryl ring of the model compound with a 
thiophenic one and its shifting to position 6, have furnished derivatives 4a-
g which were devoid of or endowed with a scarce anti-inflammatory effect. 
Central analgesic activity was occasionally present in compounds 4c and 4g, 
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Fig. 2 
Analgesic activity: hot Plate test (mouse) 
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